KM Research Hub
← 返回论文库
已完成 入排:符合 图源:可得 入排置信度 0.98

Patient-reported outcomes from the randomized ALICE trial evaluating the addition of atezolizumab to anthracycline-based chemotherapy in metastatic triple-negative breast cancer.

K G Svalheim, N K Andresen, C Bjerre, B Gilje, E H Jakobsen, R S Falk, B Naume, S Kaasa, J A Kyte

Breast 86 104704

PMID41581361
PMCIDPMC12860362
DOI10.1016/j.breast.2026.104704
发表日期2026-01-25
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:KM 曲线已提取;No. at risk 信息待人工复核,不影响当前曲线图像显示。
摘要

摘要

BACKGROUND: The ALICE trial demonstrated that adding atezolizumab to anthracycline-based immunomodulatory chemotherapy improved progression-free survival (PFS) in patients with metastatic triple-negative breast cancer (mTNBC), including those with PD-L1-negative tumors. Here, we report the patient-reported outcome measures (PROMs). METHODS: Patients were randomized to receive chemotherapy plus atezolizumab (atezo-chemo) or chemotherapy plus placebo (placebo-chemo). PROMs were collected at baseline and weeks 9, 17, 25, and 49 using the EORTC QLQ-C15-PAL, Chalder Fatigue Questionnaire (CFQ), and Numeric Rating Scale (NRS) for pain. RESULTS: PROMs were available from 64 of 68 patients. At week 9, mean changes from baseline favored the atezo-chemo arm across all QLQ-C15-PAL domains, CFQ scores, and NRS pain intensity. Time-to-deterioration analyses also favored atezo-chemo, with statistically significant hazard ratios for global quality of life (QoL; HR 0.24), emotional functioning (HR 0.30), and pain (HR 0.20). Pain-a pre-specified cardinal symptom-improved in the atezo-chemo group at all time points. At 12 months, PROMs indicated sustained tolerability. Better baseline PROM scores were associated with improved PFS and overall survival, especially among patients treated with atezolizumab. Patients with >median QoL score at baseline recorded improved PFS when treated with atezolizumab (HR 0.25), while patients with ≤median QoL score did not (HR 1.02). CONCLUSIONS: Adding atezolizumab to the study-chemotherapy in mTNBC improves both PFS and patient-reported quality of life, emotional well-being and symptom control. These findings support continued development of this combination regimen and suggest that baseline quality of life may serve as a useful predictor of immunotherapy benefit. TRIAL REGISTRATION: NCT03164993, May 24th 2017; https://clinicaltrials.gov/ct2/show/record/NCT03164993.

KM 提取结果

2 个 Figure · 12 个 KM 面板

进入结果中心
KM Figure6 个面板

Fig. 1

Fig. 1 Kaplan-Meier plots for time to deterioration in quality of life for [a] all patients, [b] PD-L1-positive and [c] PD-L1-negative, and emotional functioning for [d] all patients, [e] PD-L1-positive, [f] PD-L1-negative. P-values were calculated with log-rank test.

A

Quality of life

Fig. 1 · Panel A

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel A 是同一 Fig. 1 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
B

Quality of life

Fig. 1 · Panel B

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel B 是同一 Fig. 1 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似图例或人工水平线:轨迹出现不合理的共同平台疑似图例或人工水平线:轨迹出现不合理的共同平台曲线 1:extreme upward reversal曲线 2:extreme upward reversal
查看结果
C

Quality of life

Fig. 1 · Panel C

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel C 是同一 Fig. 1 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
D

Emotional functioning

Fig. 1 · Panel D

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel D 是同一 Fig. 1 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
E

Emotional functioning

Fig. 1 · Panel E

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel E 是同一 Fig. 1 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
F

Emotional functioning

Fig. 1 · Panel F

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel F 是同一 Fig. 1 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
KM Figure6 个面板

Fig. 5

Fig. 5 Predictive value of QoL score for benefit of atezolizumab. Kaplan-Meier plots for PFS (a) and OS (b–c), in the atezo-chemo compared to placebo-chemo arm, in patients with high (>median) or low (≤median) QoL score. Two patients in the placebo-chemo arm started therapy with PD1/PD-L1 checkpoint inhibitors after end-of-treatment in the ALICE trial. (b) OS, without censoring for any post-study therapy. (c) OS, with censoring at start of post-study PD1/PD-L1 checkpoint inhibitor therapy. Median QoL score was 66.7. P-values calculated with log-rank test. HRs were calculated by cox regression analysis.

A

PFS

Fig. 5 · Panel A

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel A 是同一 Fig. 5 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
A_2

PFS

Fig. 5 · Panel A_2

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel A_2 是同一 Fig. 5 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
B

OS

Fig. 5 · Panel B

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel B 是同一 Fig. 5 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
B_4

OS

Fig. 5 · Panel B_4

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel B_4 是同一 Fig. 5 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
C

OS

Fig. 5 · Panel C

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel C 是同一 Fig. 5 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
C_6

OS

Fig. 5 · Panel C_6

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel C_6 是同一 Fig. 5 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
其他 Figure(3,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Fig. 2Fig. 2 Time to deterioration (TTD) of PROMs in the atezo-chemo versus placebo-chemo arm. Forest plots with HRs for each PROM in [a] All patients, [b] PD-L1-positive cohort, [c] PD-L1-negative cohort. HRs, 95 % confidence intervals (CI) and p-values were calculated by cox regression analysis.
非 KM Figure
Fig. 3Fig. 3 Changes in PROMs from baseline. (a) Mean change in EORTC QLQ-C15 PAL scales. Worsening is indicated by a score < 0 for QoL and functional scales (left chart), but by a score>0 for symptom scales (right chart). (b) Mean change in Chalder Fatigue score. Worsening is indicated by a score>0. (c) Mean change in NRS pain intensity. Worsening is indicated by a score>0. Error bars represent SEM. Red dotted lines indicate the protocol-defined group-level thresholds for clinical importance. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)
非 KM Figure
Fig. 4Fig. 4 Prognostic value of baseline PROs. Forest plots with hazard ratios for PFS and OS for each PRO. (a) Data for all patients. Patients reporting better pre-treatment QoL, physical and emotional functioning had longer PFS/OS (HR < 1). For symptom scales, CFS and NRS, a HR < 1 indicate that patients with more baseline symptoms had shorter PFS/OS. (b) Data for atezo-chemo arm. (c) Data for placebo-chemo arm. HRs, 95 % confidence intervals (CI) and p-values were calculated by cox regression analysis. PRO values were analyzed as continuous variables and scaled by dividing by the standard deviation.
非 KM Figure